Research Article
BibTex RIS Cite

Novel insights into myocardial injury, diastolic pathology, and in-hospital mortality: the impact of H2FPEF score in COVID-19 patients

Year 2024, Volume: 7 Issue: 1, 89 - 97, 15.01.2024
https://doi.org/10.32322/jhsm.1402669

Abstract

Aims: H2FPEF score is a reliable tool for diagnosing heart failure with preserved ejection fraction (HFpEF) linked to diastolic dysfunction. Our objective was to explore the correlation between H2FPEF score and in-hospital mortality, as well as parameters previously identified in association with COVID-19, among hospitalized COVID-19 patients.
Methods: This prospective, single-center observational study included 205 consecutive COVID-19 hospitalized patients. Data regarding patients' clinical status, comorbidities, and drug therapy were extracted from medical histories and records. Afterward, we calculated H2FPEF score for each patient and subsequently grouped them based on the following score categories: low (0-1), medium (2-5), and high (6-9). Logistic regression and Kaplan-Meier survival curve analyses were conducted to assess in-hospital mortality and the presence of an intermediate-to-high H2FPEF score.
Results: Death occurred in 46 (22.4%) patients. 79 participants (38.5%) fell into the low-risk category (0-1 points), 108 (52.7%) were classified as intermediate-risk (2-5 points), and the remaining 18 (8.8%) were in the high-risk category (6-9 points). Age, heart rate, body mass index, and co-morbidities exhibited a rising trend with increasing H2FPEF scores (p<0.05 for all). Moreover, an escalation in the H2FPEF category correlated with deteriorated echocardiographic parameters. Multivariable logistic regression analysis revealed that heart rate per minute (OR=1.048, p=0.022), H2FPEF score (OR=1.396, p=0.018), and current smoker (OR=4.569, p=0.050) were independent determinants of in-hospital mortality. ROC curve indicated that the H2FPEF score, with a threshold of ≥2, exhibited good discriminative capacity, demonstrating 80.4% sensitivity and 69.2% specificity (AUC=0.777, p<0.001). The pairwise comparison of ROC curves analysis demonstrated that troponin (AUC=0.819) exhibited better discriminative abilities than both D-dimer (AUC=0.737, p=0.029) and hemoglobin (AUC=0.691, p=0.007) in determining an intermediate-to-high H2FPEF score.
Conclusion: COVID-19, recognized for its association with myocardial damage, could emerge as a significant risk factor for the onset of HFpEF. H2FPEF score presents as a straightforward tool for rapid risk assessment upon hospitalization, potentially aiding in the evaluation of the risk for HFpEF development. Its utilization may facilitate early intervention, thereby contributing to a reduction in poor outcomes.

Ethical Statement

Ethical Declarations Ethics Committee Approval: This study was conducted following the guidelines set by Adana City Training and Research Hospital Clinical Research Ethics Committee, with approval granted on [Date: 2022, Decision No: 1860]. If ethical approval was deemed unnecessary, a concise statement explaining the rationale is provided. Informed Consent: Given the retrospective design of the study, no written informed consent forms were obtained from the patients. Referee Evaluation Process: The study underwent external peer review. Conflict of Interest Statement: The authors declare no conflicts of interest. Financial Disclosure: The authors confirm that this study received no financial support. Author Contributions: All authors actively participated in the design, execution, and analysis of the paper, and have collectively approved the final version. Acknowledgement: None

References

  • Azevedo RB, Botelho BG, Hollanda JVGD, et al. COVID-19 and the cardiovascular system: a comprehensive review. J Hum Hypertens. 2021;35(1):4-11.
  • Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2020;17(9):559-573.
  • McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021;42(36):3599-3726.
  • John KJ, Mishra AK, Ramasamy C, George AA, Selvaraj V, Lal A. Heart failure in COVID-19 patients: critical care experience. World J Virol. 2022;11(1):1.
  • Zaccone G, Tomasoni D, Italia L, Lombardi CM, Metra M. Myocardial involvement in COVID-19: an interaction between comorbidities and heart failure with preserved ejection fraction. a further indication of the role of inflammation. Curr Heart Fail Rep. 2021;18(3):99-106.
  • Türkoğlu C, Şeker T, Genç Ö, Yıldırım A, Topuz M. The relationship between H 2 FPEF score and coronary slow flow phenomenon. Turk Kardiyol Dern Ars. 2022;50(4):242.
  • Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233-271.
  • Reddy YN, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circ. 2018;138(9):861-870.
  • De Boer RA, Nayor M, DeFilippi CR, et al. Association of cardiovascular biomarkers with incident heart failure with preserved and reduced ejection fraction. JAMA Cardiol. 2018; 3(3):215-224.
  • Chitsazan M, Amin A, Chitsazan M, et al. Heart failure with preserved ejection fraction in coronavirus disease 2019 patients: the promising role of diuretic therapy in critically ill patients. ESC Heart Fail. 2021;8(2):1610-1614.
  • Baratto C, Caravita S, Parati G. Heart failure with preserved ejection fraction and COVID‐19: which comes first, the chicken or the egg? letter regarding the article ‘Heart failure with preserved ejection fraction according to the HFA‐PEFF score in COVID‐19 patients: clinical correlates and echocardiographic findings’. ESC Heart Fail. 2021;23(12):2091.
  • Mountantonakis SE, Saleh M, Fishbein J, et al. Atrial fibrillation is an independent predictor for in-hospital mortality in patients admitted with SARS-CoV-2 infection. Heart Rhythm. 2021;18(4):501-507.
  • Pranata R, Lim MA, Huang I, Raharjo SB, Lukito AA. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis and meta-regression. J Renin Angiotensin Aldosterone Syst. 2020;21(2):1470320320926899. doi: 10.1177/1470320320926899
  • Pagnesi M, Baldetti L, Beneduce A, et al. Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19. Heart. 2020;106(17):1324-1331.
  • Sadeghi R, Toloui A, Pourhoseingholi A, et al. The prognostic value of echocardiographic findings in prediction of in-hospital mortality of COVID-19 patients. Frontiers Emerg Med. 2021;5(4):e38.
  • Palaiodimos L, Kokkinidis DG, Li W, et al. Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. Metabol. 2020;108:154262.
  • Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934-943.
  • Gallo Marin B, Aghagoli G, Lavine K, et al. Predictors of COVID‐19 severity: a literature review. Rev Med Virol. 2021;31(1):1-10.
  • Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91-95.
  • Liu Y, Sun W, Guo Y, et al. Association between platelet parameters and mortality in coronavirus disease 2019: retrospective cohort study. Platelets. 2020;31(4):490-496.
  • Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia-a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr. 2020;14(4):395-403.
  • Li L, Zhang S, He B, Chen X, Wang S, Zhao Q. Risk factors and electrocardiogram characteristics for mortality in critical inpatients with COVID‐19. Clin Cardiol. 2020;43(12):1624-1630.
  • Toraih EA, Elshazli RM, Hussein MH, et al. Association of cardiac biomarkers and comorbidities with increased mortality, severity, and cardiac injury in COVID‐19 patients: a meta‐regression and decision tree analysis. J Med Virol. 2020;92(11):2473-2488.
  • Babapoor-Farrokhran S, Gill D, Walker J, Rasekhi RT, Bozorgnia B, Amanullah A. Myocardial injury and COVID-19: possible mechanisms. Life Sci. 2020;253:117723.
  • Alıcı G, Harbalıoğlu H, Ömer G, et al. High-sensitivity cardiac troponin I and D-dimer are risk factors for in-hospital mortality of adult patients with COVID-19: a retrospective cohort study. Ege Tıp Derg. 2021;60(2):113-120.
  • Gungor B, Atici A, Baycan OF, et al. Elevated D-dimer levels on admission are associated with severity and increased risk of mortality in COVID-19: a systematic review and meta-analysis. Am J Emerg Med. 2021;39:173-179.
  • Liu F, Li L, Xu M, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol Plus. 2020;127:104370.
Year 2024, Volume: 7 Issue: 1, 89 - 97, 15.01.2024
https://doi.org/10.32322/jhsm.1402669

Abstract

References

  • Azevedo RB, Botelho BG, Hollanda JVGD, et al. COVID-19 and the cardiovascular system: a comprehensive review. J Hum Hypertens. 2021;35(1):4-11.
  • Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2020;17(9):559-573.
  • McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021;42(36):3599-3726.
  • John KJ, Mishra AK, Ramasamy C, George AA, Selvaraj V, Lal A. Heart failure in COVID-19 patients: critical care experience. World J Virol. 2022;11(1):1.
  • Zaccone G, Tomasoni D, Italia L, Lombardi CM, Metra M. Myocardial involvement in COVID-19: an interaction between comorbidities and heart failure with preserved ejection fraction. a further indication of the role of inflammation. Curr Heart Fail Rep. 2021;18(3):99-106.
  • Türkoğlu C, Şeker T, Genç Ö, Yıldırım A, Topuz M. The relationship between H 2 FPEF score and coronary slow flow phenomenon. Turk Kardiyol Dern Ars. 2022;50(4):242.
  • Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233-271.
  • Reddy YN, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circ. 2018;138(9):861-870.
  • De Boer RA, Nayor M, DeFilippi CR, et al. Association of cardiovascular biomarkers with incident heart failure with preserved and reduced ejection fraction. JAMA Cardiol. 2018; 3(3):215-224.
  • Chitsazan M, Amin A, Chitsazan M, et al. Heart failure with preserved ejection fraction in coronavirus disease 2019 patients: the promising role of diuretic therapy in critically ill patients. ESC Heart Fail. 2021;8(2):1610-1614.
  • Baratto C, Caravita S, Parati G. Heart failure with preserved ejection fraction and COVID‐19: which comes first, the chicken or the egg? letter regarding the article ‘Heart failure with preserved ejection fraction according to the HFA‐PEFF score in COVID‐19 patients: clinical correlates and echocardiographic findings’. ESC Heart Fail. 2021;23(12):2091.
  • Mountantonakis SE, Saleh M, Fishbein J, et al. Atrial fibrillation is an independent predictor for in-hospital mortality in patients admitted with SARS-CoV-2 infection. Heart Rhythm. 2021;18(4):501-507.
  • Pranata R, Lim MA, Huang I, Raharjo SB, Lukito AA. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis and meta-regression. J Renin Angiotensin Aldosterone Syst. 2020;21(2):1470320320926899. doi: 10.1177/1470320320926899
  • Pagnesi M, Baldetti L, Beneduce A, et al. Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19. Heart. 2020;106(17):1324-1331.
  • Sadeghi R, Toloui A, Pourhoseingholi A, et al. The prognostic value of echocardiographic findings in prediction of in-hospital mortality of COVID-19 patients. Frontiers Emerg Med. 2021;5(4):e38.
  • Palaiodimos L, Kokkinidis DG, Li W, et al. Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. Metabol. 2020;108:154262.
  • Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934-943.
  • Gallo Marin B, Aghagoli G, Lavine K, et al. Predictors of COVID‐19 severity: a literature review. Rev Med Virol. 2021;31(1):1-10.
  • Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91-95.
  • Liu Y, Sun W, Guo Y, et al. Association between platelet parameters and mortality in coronavirus disease 2019: retrospective cohort study. Platelets. 2020;31(4):490-496.
  • Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia-a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr. 2020;14(4):395-403.
  • Li L, Zhang S, He B, Chen X, Wang S, Zhao Q. Risk factors and electrocardiogram characteristics for mortality in critical inpatients with COVID‐19. Clin Cardiol. 2020;43(12):1624-1630.
  • Toraih EA, Elshazli RM, Hussein MH, et al. Association of cardiac biomarkers and comorbidities with increased mortality, severity, and cardiac injury in COVID‐19 patients: a meta‐regression and decision tree analysis. J Med Virol. 2020;92(11):2473-2488.
  • Babapoor-Farrokhran S, Gill D, Walker J, Rasekhi RT, Bozorgnia B, Amanullah A. Myocardial injury and COVID-19: possible mechanisms. Life Sci. 2020;253:117723.
  • Alıcı G, Harbalıoğlu H, Ömer G, et al. High-sensitivity cardiac troponin I and D-dimer are risk factors for in-hospital mortality of adult patients with COVID-19: a retrospective cohort study. Ege Tıp Derg. 2021;60(2):113-120.
  • Gungor B, Atici A, Baycan OF, et al. Elevated D-dimer levels on admission are associated with severity and increased risk of mortality in COVID-19: a systematic review and meta-analysis. Am J Emerg Med. 2021;39:173-179.
  • Liu F, Li L, Xu M, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol Plus. 2020;127:104370.
There are 27 citations in total.

Details

Primary Language English
Subjects Cardiology
Journal Section Original Article
Authors

Ömer Genç 0000-0002-9097-5391

Abdullah Yıldırım 0000-0002-7071-8099

Gökhan Alıcı 0000-0002-4589-7566

Tayfur Erdoğdu 0000-0003-2503-9393

Örsan Deniz Urgun 0000-0001-9125-4732

Aslan Erdoğan 0000-0002-1094-5572

Eyüp Özkan 0000-0003-0792-628X

Şerafettin Demır 0000-0002-1735-5049

Early Pub Date January 15, 2024
Publication Date January 15, 2024
Submission Date December 10, 2023
Acceptance Date December 27, 2023
Published in Issue Year 2024 Volume: 7 Issue: 1

Cite

AMA Genç Ö, Yıldırım A, Alıcı G, Erdoğdu T, Urgun ÖD, Erdoğan A, Özkan E, Demır Ş. Novel insights into myocardial injury, diastolic pathology, and in-hospital mortality: the impact of H2FPEF score in COVID-19 patients. J Health Sci Med / JHSM. January 2024;7(1):89-97. doi:10.32322/jhsm.1402669

Interuniversity Board (UAK) Equivalency: Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS].

The Directories (indexes) and Platforms we are included in are at the bottom of the page.

Note: Our journal is not WOS indexed and therefore is not classified as Q.

You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. https://dergipark.org.tr/tr/journal/2316/file/4905/show







The indexes of the journal are ULAKBİM TR Dizin, Index Copernicus, ICI World of Journals, DOAJ, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, WorldCat (OCLC), MIAR, EuroPub, OpenAIRE, Türkiye Citation Index, Türk Medline Index, InfoBase Index, Scilit, etc.

       images?q=tbn:ANd9GcRB9r6zRLDl0Pz7om2DQkiTQXqDtuq64Eb1Qg&usqp=CAU

500px-WorldCat_logo.svg.png

atifdizini.png

logo_world_of_journals_no_margin.png

images?q=tbn%3AANd9GcTNpvUjQ4Ffc6uQBqMQrqYMR53c7bRqD9rohCINkko0Y1a_hPSn&usqp=CAU

doaj.png  

images?q=tbn:ANd9GcSpOQFsFv3RdX0lIQJC3SwkFIA-CceHin_ujli_JrqBy3A32A_Tx_oMoIZn96EcrpLwTQg&usqp=CAU

ici2.png

asos-index.png

drji.png





The platforms of the journal are Google Scholar, CrossRef (DOI), ResearchBib, Open Access, COPE, ICMJE, NCBI, ORCID, Creative Commons, etc.

COPE-logo-300x199.jpgimages?q=tbn:ANd9GcQR6_qdgvxMP9owgnYzJ1M6CS_XzR_d7orTjA&usqp=CAU

icmje_1_orig.png

cc.logo.large.png

ncbi.pngimages?q=tbn:ANd9GcRBcJw8ia8S9TI4Fun5vj3HPzEcEKIvF_jtnw&usqp=CAU

ORCID_logo.png

1*mvsP194Golg0Dmo2rjJ-oQ.jpeg


Our Journal using the DergiPark system indexed are;

Ulakbim TR Dizin,  Index Copernicus, ICI World of JournalsDirectory of Research Journals Indexing (DRJI), General Impact FactorASOS Index, OpenAIRE, MIAR,  EuroPub, WorldCat (OCLC)DOAJ,  Türkiye Citation Index, Türk Medline Index, InfoBase Index


Our Journal using the DergiPark system platforms are;

Google, Google Scholar, CrossRef (DOI), ResearchBib, ICJME, COPE, NCBI, ORCID, Creative Commons, Open Access, and etc.


Journal articles are evaluated as "Double-Blind Peer Review". 

Our journal has adopted the Open Access Policy and articles in JHSM are Open Access and fully comply with Open Access instructions. All articles in the system can be accessed and read without a journal user.  https//dergipark.org.tr/tr/pub/jhsm/page/9535

Journal charge policy   https://dergipark.org.tr/tr/pub/jhsm/page/10912


Editor List for 2022

Assoc. Prof. Alpaslan TANOĞLU (MD)  

Prof. Aydın ÇİFCİ (MD)

Prof. İbrahim Celalaettin HAZNEDAROĞLU (MD)

Prof. Murat KEKİLLİ (MD)

Prof. Yavuz BEYAZIT (MD) 

Prof. Ekrem ÜNAL (MD)

Prof. Ahmet EKEN (MD)

Assoc. Prof. Ercan YUVANÇ (MD)

Assoc. Prof. Bekir UÇAN (MD) 

Assoc. Prof. Mehmet Sinan DAL (MD)


Our journal has been indexed in DOAJ as of May 18, 2020.

Our journal has been indexed in TR-Dizin as of March 12, 2021.


17873

Articles published in the Journal of Health Sciences and Medicine have open access and are licensed under the Creative Commons CC BY-NC-ND 4.0 International License.